CAPTRUST Financial Advisors
EGRX

CAPTRUST Financial Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-439
Closed -$20K – 4252
2022
Q2 		$20K Hold
439
– – ﹤0.01% 3387
2022
Q1 		$22K Buy
439
+373
+565% +$17.9K ﹤0.01% 3333
2021
Q4 		$3K Buy
66
+15
+29% +$777 ﹤0.01% 4321
2021
Q3 		$3K Hold
51
– – ﹤0.01% 4170
2021
Q2 		$2K Buy
51
+9
+21% +$371 ﹤0.01% 4223
2021
Q1 		$2K Buy
42
+17
+68% +$789 ﹤0.01% 4093
2020
Q4 		$1K Buy
+25
New +$1.17K ﹤0.01% 3336

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAPTRUST Financial Advisors's EGRX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 439 shares — an estimated $20K sold.

CAPTRUST Financial Advisors first reported a position in EGRX in Q4 2020 and held it in 7 quarters. The position peaked at $22K in Q1 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 439 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $20K.
  • CAPTRUST Financial Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Eagle Pharmaceuticals, Inc. position peaked at $22K in Q1 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.